Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Lasagna

Showing results (101-110 of 199) with videos related to

Pageof 20
Sort By:
JAMA|November 14, 1986
The economics of generic prescribing: winners and losersL Lasagna
Clinical Therapeutics|January 1, 1987
Does the public need protection from itself?L Lasagna
The Journal of Allergy and Clinical Immunology|July 1, 1986
The placebo effectL Lasagna
Journal of Chronic Diseases|January 1, 1987
Ethics and informed consentL Lasagna
Clinical Pharmacology and Therapeutics|October 23, 1997
Issues in pharmaceutical lotteries: the case of interferon beta-1bM Manocchia, L Lasagna
Clinical Pharmacology and Therapeutics|December 1, 1975
Patient package inserts. II. Toward a rational patient package insertP Joubert, L Lasagna
Clinical Pharmacology and Therapeutics|November 1, 1975
Commentary: Patient package inserts. I. Nature, notions, and needsP Joubert, L Lasagna
American Journal of Clinical Oncology|August 1, 1996
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials ConferenceL Lasagna, E Frei
Regulatory Toxicology and Pharmacology : RTP|June 1, 1985
From DNA to NDA--the impact of recombinant DNA technology on new drug developmentS O Waife, L Lasagna
JAMA|December 22, 1975
Adverse drug reactions. A critical reviewF E Karch, L Lasagna
Pageof 20

Showing results (101-110 of 199) with videos related to

Sort By:
Pageof 20
JAMA|November 14, 1986
The economics of generic prescribing: winners and losersL Lasagna
Clinical Therapeutics|January 1, 1987
Does the public need protection from itself?L Lasagna
The Journal of Allergy and Clinical Immunology|July 1, 1986
The placebo effectL Lasagna
Journal of Chronic Diseases|January 1, 1987
Ethics and informed consentL Lasagna
Clinical Pharmacology and Therapeutics|October 23, 1997
Issues in pharmaceutical lotteries: the case of interferon beta-1bM Manocchia, L Lasagna
Clinical Pharmacology and Therapeutics|December 1, 1975
Patient package inserts. II. Toward a rational patient package insertP Joubert, L Lasagna
Clinical Pharmacology and Therapeutics|November 1, 1975
Commentary: Patient package inserts. I. Nature, notions, and needsP Joubert, L Lasagna
American Journal of Clinical Oncology|August 1, 1996
The impact of regulations, tradition, and experimental design on clinical cancer trials: report and recommendations resulting from Washington Cancer Trials ConferenceL Lasagna, E Frei
Regulatory Toxicology and Pharmacology : RTP|June 1, 1985
From DNA to NDA--the impact of recombinant DNA technology on new drug developmentS O Waife, L Lasagna
JAMA|December 22, 1975
Adverse drug reactions. A critical reviewF E Karch, L Lasagna
Pageof 20